Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | G6PD | P11413 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.36 |
| ▸ | MIF | P14174 | 1/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | CHUK | O15111 | 1/20 | 0.34 |
| ▸ | STS | P08842 | 1/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31586680 | 0.79 | KDM4E (0.48) | G6PDALDH1A1ABCC9MIFHTT | |
| SCHEMBL2615998 | 0.75 | GRM4 (0.40) | ALDH1A1CYP2A6GRM4MAPT | |
| SCHEMBL31165729 | 0.72 | GRM4 (0.41) | ALDH1A1GRM4MAPTGAA | |
| SCHEMBL7377972 | 0.72 | GRM4 (0.38) | ALDH1A1GRM4MAPT | |
| SCHEMBL855507 | 0.72 | GRM4 (0.41) | ALDH1A1GRM4MAPTGAA | |
| SCHEMBL17826978 | 0.72 | GRM4 (0.38) | ALDH1A1GRM4MAPT | |
| SCHEMBL10164894 | 0.72 | EPAS1 (0.38) | ALDH1A1CYP2A6GRM4HTTCASP3 | |
| SCHEMBL3160662 | 0.70 | STS (0.46) | G6PDALDH1A1CYP2A6MIFCHUK | |
| SCHEMBL30506249 | 0.69 | ALDH1A1 (0.43) | ALDH1A1CYP2A6CHUKCASP3 | |
| SCHEMBL20116697 | 0.69 | ALDH1A1 (0.43) | ALDH1A1CYP2A6CHUKCASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-7795245-B2 | Heterobicyclic metalloprotease inhibitors | Atlantos Pharmaceuticals Holding, Inc. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795245-B2 | Heterobicyclic metalloprotease inhibitors | Atlantos Pharmaceuticals Holding, Inc. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | MMP13, TIMP3, MMP3 | G6PD 4436/4885ALDH1A1 1806/4885CYP2A6 615/4885 |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | MMP13, TIMP3, MMP3 | G6PD 4436/4885ALDH1A1 1806/4885CYP2A6 615/4885 |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | G6PD 4436/4885ALDH1A1 1806/4885CYP2A6 615/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | G6PD 4436/4885ALDH1A1 1806/4885CYP2A6 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.